Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for N-acetylcysteine  COVID-19 treatment studies for N-acetylcys..  C19 studies: N-acetylcys..  N-acetylcys..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Hospitalization -83% Improvement Relative Risk Recovery time -18% c19early.org/na Ghayour et al. IRCT20220302054167N1 N-acetylcysteine RCT EARLY Is early treatment with N-acetylcysteine beneficial for COVID-19? RCT 150 patients in Iran (April - September 2022) Trial compares with bromhexine, results vs. placebo may differ Higher hospitalization (p=0.3) and slower recovery (p=0.094), not stat. sig. Ghayour et al., Research Square, doi:10.21203/rs.3.rs-2309373/v1 Favors N-acetylcysteine Favors bromhexine
Evaluation of the recovery rate and prevention of hospitalization among covid-19 outpatients: a randomized clinical trial comparing N-acetylcysteine with Bromhexine
Ghayour et al., Research Square, doi:10.21203/rs.3.rs-2309373/v1 (Preprint), IRCT20220302054167N1
Ghayour et al., Evaluation of the recovery rate and prevention of hospitalization among covid-19 outpatients: a randomized.., Research Square, doi:10.21203/rs.3.rs-2309373/v1 (Preprint), IRCT20220302054167N1
Jan 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 150 outpatients in Iran comparing N-acetylcysteine and bromhexine, showing lower hospitalization and faster recovery with bromhexine, without statistical significance. Baseline information per group is not provided, and Figure 1 appears to have the two groups switched and an incorrect value for the not hospitalized total in one group. N-acetylcysteine 600mg daily for 5 days, bromhexine 8mg tid for 5 days. This study is excluded in the after exclusion results of meta analysis: results unclear due to errors in the preprint, baseline group details not provided.
risk of hospitalization, 83.3% higher, RR 1.83, p = 0.30, treatment 11 of 75 (14.7%), control 6 of 75 (8.0%).
recovery time, 17.6% higher, relative time 1.18, p = 0.09, treatment 75, control 75.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ghayour et al., 3 Jan 2023, Randomized Controlled Trial, Iran, preprint, mean age 58.6, 4 authors, study period April 2022 - September 2022, this trial compares with another treatment - results may be better when compared to placebo, trial IRCT20220302054167N1.
Contact: anahitaeslami1995@gmail.com.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperN-acetylcys..All
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit